Amgen Plans 2017 Filings After Second Phase III CGRP Inhibitor Success
A second Phase III success for erenumab keeps Amgen on track to seek regulatory approvals in 2017, which means the company could win the first US FDA approval for a CGRP inhibitor to treat migraine headaches.